1. Total androgen ablation: Canadian experience;Beland, G.; Elhilali, M.; Fradet, Y.; Laroche, B.; Ramsey, E.W.; Trachtenberg, J.;Urol Clin North Am,1991
2. Phase II study of the pure nonsteroidal antiandrogen nilutamide in prostatic cancer;Decensi, A.; Guarneri, D.; Paoletti, M.C.; Lalanne, J.M.; Merlo, F.; Boccardo, F.;Eur J Cancer,1991
3. Pulmonary complications ofhormone treatment in prostate carcinoma;Seigneur, J.; Trechot, P.; Hubert, J.; Lamy, P.;Chest,1988
4. Pneumopathie interstitielle d'origine medicamenteuse: le nilutamide (Anandron);Ode, P.; Guy, C.; Rousse, T.H.; Ollagnier, M.; Guerin, J.C.;Rev Mal Respir,1988
5. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis;Akoun, G.M.; Liote, H.A.; Liote, F.; Gauthier-Rahman, S.; Kuntz, D.;Chest,1990